Herath Nalaka, Ratnatunga Neelakanthi, Weerakoon Kosala, Wazil Abdul, Nanayakkara Nishantha
Nephrology Unit, Teaching Hospital, Karapitiya, Galle, Sri Lanka.
Department of Pathology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka.
BMC Res Notes. 2017 Feb 2;10(1):80. doi: 10.1186/s13104-017-2402-6.
Despite the improvement in survival of patients with lupus nephritis (LN) globally, there is sparse data from Sri Lanka (SL). The current study aims to describe the clinicopathological findings, treatment response and predictors of long-term outcome of patients with WHO class III-IV LN in SL, managed according to the Euro-lupus regime.
Of 72 patients, 64 were females. In half of them, LN was diagnosed within the 1st year of the illness. The most common presenting feature was sub-nephrotic proteinuria. Sixteen and twenty patients had nephrotic syndrome and abnormal renal function respectively at the time of diagnosis. Fifty-four patients (75%) responded to the Euro-lupus regimen [CR, 20 (28%); PR, 34(47%)]. Later at 6 months, 65 patients (90%) achieved remission [CR, 31(43%); PR, 34 (47%)]. Seven patients experienced treatment failure. During the total duration of follow up, 54 patients remained in complete or partial remission, 26 developed renal relapses, and 19 suffered severe infective episodes. Renal relapses were more common in people who achieved partial remission than complete remission. The long term renal outcome was not associated with age, sex, severity of proteinuria, class of LN or initial renal function. Patients who achieved remission at 6 months had a good long-term outcome.
The demographic and clinical features of WHO class III and IV LN in Sri Lankan patients were similar to that reported in the global literature. 75% of patients responded to the Euro-lupus regimen. Therefore, this regime is a suitable initial regimen for LN patients in SL. Good long-term renal outcome can be predicted by early response to therapy. Further studies are necessary to explore better treatment options for patients who fail to achieve remission during initial therapy.
尽管全球狼疮性肾炎(LN)患者的生存率有所提高,但来自斯里兰卡(SL)的数据却很少。本研究旨在描述斯里兰卡按照欧洲狼疮治疗方案管理的WHO III-IV级LN患者的临床病理特征、治疗反应及长期预后的预测因素。
72例患者中,64例为女性。其中一半患者在发病第1年内被诊断为LN。最常见的表现特征是亚肾病范围蛋白尿。诊断时分别有16例和20例患者患有肾病综合征和肾功能异常。54例患者(75%)对欧洲狼疮治疗方案有反应[完全缓解(CR),20例(28%);部分缓解(PR),34例(47%)]。6个月后,65例患者(90%)实现缓解[CR,31例(43%);PR,34例(47%)]。7例患者治疗失败。在整个随访期间,54例患者保持完全或部分缓解,26例出现肾脏复发,19例发生严重感染事件。部分缓解的患者比完全缓解的患者肾脏复发更常见。长期肾脏预后与年龄、性别、蛋白尿严重程度、LN分级或初始肾功能无关。6个月时实现缓解的患者长期预后良好。
斯里兰卡患者中WHO III级和IV级LN的人口统计学和临床特征与全球文献报道相似。75%的患者对欧洲狼疮治疗方案有反应。因此,该方案是斯里兰卡LN患者合适的初始治疗方案。早期治疗反应可预测良好的长期肾脏预后。有必要进一步研究,为初始治疗未实现缓解的患者探索更好的治疗选择。